Sino Biopharmaceutical Limited Share Price and Company Fundamentals
Last traded: Today at 8:08 AM
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Key Metrics
PE ratio
5.00
PB ratio
2.28
Dividend yield
1.53%
Beta
0.61
Market cap
-
Enterprise value
-
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 25579 |
| Website | https://www.sinobiopharm.com |
| Mailing address | Office Tower Unit 09, 41st Floor, Room 4109 Convention Plaza 1 Harbour Road Wan Chai Hong Kong |
| Phone / Fax | 852 2802 9886 / |
Dividends
Dividend yield
1.53%
Dividend amount
$0.06
Payout ratio
4.54%
5Y Avg. yield
0.72%
Sino Biopharmaceutical Limited paid $0.06 dividend and the ex-dividend date was 15 June 2022.The dividend payout ratio is 4.54%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.1177 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
1177's forward dividend amount is $0.16 and the forward dividend yield is 3.77%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of May 2022, following are the company executives and directors listed on Sino Biopharmaceutical Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Ms. Y. Y. Tse | Exec. Chairman | 29 | 5.25M |
| Mr. Yi Li | CEO & Exec. Director | 59 | 4.28M |
| Mr. Ping Tse | Founder & Sr. Vice Chairman | 69 | 6.26M |
| Ms. Cheung Ling Cheng | Exec. Vice Chairwoman of the Board | 57 | 4.42M |
| Ms. Mingqin Li | VP & Exec. Director | 62 | 179.26k |
| Mr. Zhoushan Tian | Exec. Director | 57 | 270.99k |
| Mr. Hsin Tse | VP & Exec. Director | 51 | 871.38k |
| Mr. Shanchun Wang | Exec. Director | 53 | 1.16M |
| Mr. Eric S. Y. Tse | Exec. Director | 25 | 3.45M |
| Ms. Jiayin Jennie Ma | Group Chief Financial Officer | 45 |
Profitability and management effectiveness
Profit margin
54.38%
Operating margin
15.74%
Return on assets
4.91%
Return on equity
55.25%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Sino Biopharmaceutical Limited is and its enterprise value is .
The 1177's stocks Beta value is 0.61 making it 39% less volatile compared to HKEX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Sino Biopharmaceutical Limited (HKEX:1177) Frequently Asked Questions
1. What is Sino Biopharmaceutical Limited's Stock Symbol?
Sino Biopharmaceutical Limited trades on HKEX under the ticker symbol "1177".
2. What is Sino Biopharmaceutical Limited's stock price today?
One share of 1177 stock can currently be purchased for approximately $4.27.
3. How can I contact Sino Biopharmaceutical Limited?
Sino Biopharmaceutical Limited's mailing address is Office Tower Unit 09, 41st Floor, Room 4109 Convention Plaza 1 Harbour Road Wan Chai Hong Kong. The company can be reached via phone at 852 2802 9886.
4. What is Sino Biopharmaceutical Limited's official website?
The official website of Sino Biopharmaceutical Limited is https://www.sinobiopharm.com.